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Abstract
The hypothalamic-pituitary-adrenal (HPA) axis is a major system maintaining body homeostasis by regulating the
neuroendocrine and sympathetic nervous systems as well modulating immune function. Recent work has shown that the
complex dynamics of this system accommodate several stable steady states, one of which corresponds to the hypocortisol
state observed in patients with chronic fatigue syndrome (CFS). At present these dynamics are not formally considered in
the development of treatment strategies. Here we use model-based predictive control (MPC) methodology to estimate
robust treatment courses for displacing the HPA axis from an abnormal hypocortisol steady state back to a healthy cortisol
level. This approach was applied to a recent model of HPA axis dynamics incorporating glucocorticoid receptor kinetics. A
candidate treatment that displays robust properties in the face of significant biological variability and measurement
uncertainty requires that cortisol be further suppressed for a short period until adrenocorticotropic hormone levels exceed
30% of baseline. Treatment may then be discontinued, and the HPA axis will naturally progress to a stable attractor defined
by normal hormone levels. Suppression of biologically available cortisol may be achieved through the use of binding
proteins such as CBG and certain metabolizing enzymes, thus offering possible avenues for deployment in a clinical setting.
Treatment strategies can therefore be designed that maximally exploit system dynamics to provide a robust response to
treatment and ensure a positive outcome over a wide range of conditions. Perhaps most importantly, a treatment course
involving further reduction in cortisol, even transient, is quite counterintuitive and challenges the conventional strategy of
supplementing cortisol levels, an approach based on steady-state reasoning.
Citation: Ben-Zvi A, Vernon SD, Broderick G (2009) Model-Based Therapeutic Correction of Hypothalamic-Pituitary-Adrenal Axis Dysfunction. PLoS Comput
Biol 5(1): e1000273. doi:10.1371/journal.pcbi.1000273
Editor: Simon M. Lin, Northwestern University, United States of America
Received May 30, 2008; Accepted December 11, 2008; Published January 23, 2009
Copyright:  2009 Ben-Zvi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was jointly funded by GB and by AB-Z through funds provided by the Faculty of Medicine and Dentistry at the University of Alberta and the
Natural Sciences and Engineering Research Council of Canada, respectively.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gordon.broderick@ualberta.ca
Introduction
The hypothalamic-pituitary-adrenal (HPA) axis constitutes one
of the major peripheral outflow systems of the brain, serving to
maintain body homeostasis by adapting the organism to changes
in the external and internal environments. It does this by
regulating the neuroendocrine and sympathetic nervous systems
as well modulating immune function [1]. Through regulation of
these systems, the HPA axis initiates and coordinates responses to
physical stressors; such as infection, hemorrhage, dehydration,
thermal exposure and to neurogenic stressors; such as fear,
anticipation and fight or flight.
Many aspects of the organization and function of the HPA axis
have been characterized in clinical and laboratory studies
revealing a number of component feedback and feed forward
signaling processes. Stress activates the release of corticotropin-
releasing hormone (CRH) from the paraventricular nucleus (PVN)
of the hypothalamus. The release of CRH into the hypophysial-
portal circulation in turn acts in conjunction with arginine
vasopressin on CRH-R1 receptors of the anterior pituitary
stimulating the rapid release of adrenocorticotropic hormone
(ACTH). ACTH then is released into the peripheral circulation
and stimulates the release of the glucocorticoid cortisol from the
adrenal cortex by acting on the receptor MC2-R (type 2
melanocortin receptor). Cortisol enters the cell and binds to the
glucocorticoid receptor present in the cytoplasm of every
nucleated cell; hence the widespread effects of glucocorticoids on
practically every system of the body including endocrine, nervous,
cardiovascular and immune systems.
To keep HPA axis activity in check, glucocorticoids also exert
negative feedback at the hypothalamus and pituitary glands to
inhibit the synthesis and secretion of CRH and ACTH,
respectively. Moreover, glucocorticoid negative feedback causes
a reduction in corticotroph receptor expression leading to a
desensitization of the pituitary to the stimulatory effects of CRH
on ACTH release. This negative feedback is also felt in the
hippocampus where it exerts a negative influence on the PVN. A
detailed review of the physiology and biochemistry of the HPA
axis as well as it’s know interactions with the immune system may
be found in work by Silverman et al. [2].
A number of chronic diseases have been characterized by
abnormalities in HPA axis regulation. These include major
depression and its subtypes, anxiety disorders such as post-
traumatic stress disorder, panic disorder and cognitive disorders
such as Alzheimer’s disease and minimal cognitive impairment of
aging [3]. Dysregulation of the HPA axis has also been linked to
the pathophysiology of Gulf War illness [4], post-infective fatigue
[5], and chronic fatigue syndrome (CFS) [6,7]. It is not clear what
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disorders as a hypercortisol or hypocortisol state. The existence of
these separate and stable states is not surprising when one
considers the multiple feedforward and feedback mechanisms that
regulate the HPA axis. Systems such as this often display complex
dynamics that readily accommodate multiple stable steady states
which are known as attractors because the system is naturally
drawn back to these resting states after perturbation. However, if
the perturbation is of sufficient strength and duration, the system
can be pushed away from a given resting state and into the basin of
new attractor.
Though much is known about its components, one of the main
difficulties in studying the behavior of the HPA axis has been in
integrating the expansive body of published experimental
information. Numerical models provide an ideal framework for
such integration. Simple models of the HPA axis have been
constructed using deterministic coupled ordinary differential
equations [8,9]. Though successful in reproducing some of the
basic features of HPA axis dynamics these early models neglected
to include feedback and feed-forward immune effector molecules
and associated mechanisms. Linear approximations of some
components lead to unrealistic predictions beyond a very narrow
region of concentrations. In addition transport processes involved
in the distribution of these chemical signals from the brain
throughout the body were not modeled explicitly. This level of
abstraction made direct comparison of simulation results to actual
HPA axis chemistry and physiology highly tenuous. In a move
towards increased fidelity Gupta et al. [10] introduced a more
detailed description of glucocorticoid receptor dynamics enabling
the latter to demonstrate bistability in HPA axis dynamics. As
mentioned previously this theoretical proof of the existence of a
second stable steady state is highly compatible with clinical
observations. Moreover the abnormally low cortisol levels
characterizing this stable resting state or basin of attraction are
consistent with documented observations of hypocorticolism in
patients with CFS [11], Gulf War illness and other similar
conditions [12–14].
In this work we adopt the model proposed by Gupta et al. [10]
as a recent and detailed representation of the HPA axis. On the
basis of this model we propose a framework for estimating robust
corrective measures for displacing the HPA axis from a chronic
hypocortisol state back to a healthy state. Using model-based
predictive control (MPC) methodology we demonstrate that it is
possible to compute such treatment time courses while dealing
with the inherently high level of uncertainty characteristic of
biological systems. While this uncertainty might lead to compro-
mises in efficiency, interventions can be computed that predict a
positive outcome. Our analysis indicates that one such treatment
could involve a pharmacologically induced reduction in cortisol
forcing a build-up of ACTH. Upon reaching a specific threshold
concentration of ACTH, the intervention is discontinued and the
HPA axis will return to a healthy steady state under its own
volition as this is now the closest attractor for the system.
Methods
The HPA Axis Model
A model of the HPA axis which includes glucocorticoid receptor
and the dynamics of glucocorticoid receptor-cortisol interactions
have been proposed by Gupta et al. [10]. This model is described
by the following differential equations as System H (Eq. 1).
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The system states are given as x=[x1;x 2;x 3;x 4]
T and are
described in Table 1. Note that the states in this model are scaled
values, as described by Gupta et al. [10]. The system parameters
are given by the vector p=[ki1;k cd;k ad;k i2;k cr;k rd;k ]
T. Nominal
values for the system parameters are listed in Table 2. The
variable d in System H is the stress term which describes the effect
of stress (both physical and psychological) on the hypothalamus.
This variable is seen as a disturbance that perturbs the System H
from a steady-state value.
Control of the HPA Axis System
In this first analysis the HPA axis system is considered under
idealized conditions where all parameters are assumed constant and
precisely known. In addition, the states x are assumed known as a
function of time with no measurement error and the control action is
implemented perfectly. The approach taken for choosing an optimal
control is based on the Model Predictive Control (MPC) framework
Table 1. Steady-state values for concentrations of CRH,
ACTH, free GR and circulating cortisol.
State Description Stable Rest Points
x1 CRH concentration (0.6261, 0.6610)
x2 ACTH concentration (0.0597, 0.0513)
x3 Free GR concentration (0.0809, 0.5629)
x4 Cortisol concentration (0.0597, 0.0513)
doi:10.1371/journal.pcbi.1000273.t001
Author Summary
The hypothalamic-pituitary-adrenal (HPA) axis is one of the
body’s major control systems helping to regulate functions
ranging from digestion to immune response to metabo-
lism. Dysregulation of the HPA axis is associated with a
number of neuroimmune disorders including chronic
fatigue syndrome (CFS), depression, Gulf War illness
(GWI), and posttraumatic stress disorder (PTSD). Objective
diagnosis and targeted treatments of these disorders have
proven challenging because they present no obvious
lesion. However, the body’s various components do not
work in isolation, and it is important to consider exactly
how their interactions might be altered by disease. Using a
relatively simple mathematical description of the HPA axis,
we show how the complex dynamical behavior of this
system will readily accommodate multiple stable resting
states, some of which may correspond to chronic loss of
function. We propose that a well-directed push given at
the right moment may encourage the axis to reset under
its own volition. We use model-based predictive control
theory to compute such a push. The result is counterin-
tuitive and challenges the conventional time-invariant
approach to disease and therapy. Indeed we demonstrate
that in some cases it might be possible to exploit the
natural dynamics of these physiological systems to
stimulate recovery.
HPA Axis Corrective Control
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manipulated and measured variables is defined. Typically the
objective function is a mathematical expression which corresponds
toengineeringobjectivesorunderlyingsystemconstraints.The input
computed under the MPC framework is the one in a class of
permissible inputs that minimizes the chosen objective function.
In this work it is assumed that the variable to be manipulated for
treatmentistherateofadditionorremovalofcortisolfromcirculation.
To model this control action, System H is augmented with a control
term u in the equation for cortisol (x4) (Eq. 2). Note that System Hu is
affine with respect to the control action and the disturbance.
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To avoid dangerous destabilization of the HPA axis by the
application of control action u(t) we define the following penalty
function to enforce minimal departure from normal ACTH (x2)
and cortisol (x4) levels even though we purposely manipulate
circulating cortisol to perturb the system Hu.
J~
ð tf
t~t0
xt ðÞ {x  ðÞ
TQxt ðÞ {x  ðÞ zut ðÞ
TRut ðÞdt
Where t0 and tf are the start and end time of the optimization
horizon, l is a tuning parameter taking values from zero to one
and x2
* and x4
* are the healthy steady-state concentrations of
ACTH and cortisol, respectively. R is a penalty assigned to the
input and Q is the penalty assigned to the state variables. R was
chosen as 0 because the cost for therapy was considered negligible
compared to the cost of ongoing disability. Q was chosen as follows
because x2 and x4 are the only measured states.
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000 0
0 l 00
000 0
0001 {l
2
6 6 6 4
3
7 7 7 5
The resulting cost function can be written as:
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The parameter l is used to penalize excessive imbalance of the
other hormones (x1,x 2,x 3) in response to the control action
applied to cortisol (x4). In this case, the objective of the controller is
to bring the cortisol concentration to set point while minimizing
the impact of the treatment on the other three states of the HPA
axis. Any change in CRH (x1) or the glucocorticoid receptor (GR;
x3) will be reflected in the concentration of ACTH (x2) by virtue of
the coupled dynamics described by System Hu. The tuning
parameter l can be selected to match the intensity of the desired
treatment. A l value of near zero will lead to a more intense
treatment while a value of l near one will lead to very conservative
treatment. For proof of concept, a more direct treatment was
favored in this work and a l value of 0.01 was used throughout.
Note that x2
* and x4
* correspond to the stable steady state of the
unperturbed system (i.e., when u=0). As a result, once the system
has been brought to the healthy steady state it will stay at this
steady state even if the external control action (treatment) is
removed.
Typically, a treatment or control action is applied at discrete
intervals. As a result, the objective function in Equation 3 was
optimized with respect to a piece-wise constant input signal
x4(u(t)). That is, the optimization procedure searched for an
optimal input in the set Uc of all piecewise constant functions on
T~ t0; tf ½  5<z defined such that the input level may be changed
every 1/2 scaled time unit. The optimization problem was
therefore posed in Equation 4 as:
u [
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2
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4
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The initial condition, x(t=t0) is the steady state of the
unperturbed system with d0=0. The optimal control, u [Uc was
computed using Matlab’s built-in ‘‘fminsearch’’ function.
Results
Steady-State Analysis
The steady-state solutions for HPA axis model described above
as System H can be computed by setting _ x x~0 and treating the
right side of System H as a set of four algebraic equations in the
four unknowns {x1;x 2;x 3;x 4}. Under this framework, the
disturbance variable, d, is assumed to take on a constant value
d0[<. At steady state the system is therefore described by the
following equations (Eq. 5–8).
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Table 2. Parameter settings for the differential equation
model of the HPA axis proposed by Gupta et al. [10].
Parameter Description Value
ki1 Inhibition constant for CRH synthesis 0.100
kcd CRH degradation constant 1.000
ki2 Inhibition constant for ACTH synthesis 0.100
kad ACTH degradation constant 10.000
kcr GR synthesis constant 0.050
krd GR degradation constant 0.900
k Inhibition constant for GR synthesis 0.001
doi:10.1371/journal.pcbi.1000273.t002
HPA Axis Corrective Control
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The above is a set of polynomials in x, with real coefficients, and
maximum total degree of five. Equations 5 to 8 can be simplified
using the theory of polynomial ideals [18]. Specifically, the latter
can be reduced to the following set of equations (Eq. 9–12).
f3 x3,d0 ðÞ ~0 ð9Þ
f1 x3,d0 ðÞ ~x1 ð10Þ
f2 x3,d0 ðÞ ~x2 ð11Þ
f4 x3,d0 ðÞ ~x4 ð12Þ
Therein f3 is a polynomial in x3 of degree seven, and f1,f 2 and f4
are functions only of x3 and d0. The functions f1 to f4 can be
computed using a symbolic algebra package such as Maple. For
the nominal parameter values proposed in Gupta et al. [10] there
are at most three real-valued solutions for x3 and these correspond
to the roots of f3. Each root is a steady-state value for x3 and can be
used to generate the corresponding values of x1,x 2 and x4 given
Equations 10 to 12. Note that at steady state x2=x 4 (Eq. 8). A plot
of the steady-state values of x1,x 2 and x3 as a function of d0 is
shown in Figure 1.
In this model of HPA axis dynamics a chronically stressed
individual would occupy the stable steady state associated with
a depressed cortisol concentration (,0 . 0 5 )a tr e s to ra td 0=0.If
a healthy person were subjected to extreme stress (i.e.,
d0.0.168) for an extended period of time their body would
reach the only steady state available locally that is one
corresponding to chronic stress. In other words, for values of
d0 greater than 0.168, Equation (9) dictates that there is only
one steady-state solution for free GR (x3) concentration as
opposed to the 3 solutions available for 0#d0,0.168. By virtue
of Equation (12) this results in only one steady-state solution
being available for cortisol (x4)f o rd 0.0.168. When the stress is
removed (i.e., d0=0), the body will stay at this new depressed
steady-state value of cortisol concentration. This process is
shown graphically in Figure 2 by the red dashed trajectory.
According to this model the inability of the body to return to
the healthy steady state is due to the fact that once the body
establishes a new equilibrium it inherently seeks to stay near
this point. In order to force the body to return to its original
equilibrium its state must first be shifted to a point where the
only stable condition in proximity is one corresponding to this
original healthy state. Once this is done, the internal regulatory
mechanisms of the body will ensure that this healthy stable
point is achieved and maintained. This approach is illustrated
in Figure 2 by the green dashed trajectory. The design of such a
shift is presented in the following section.
Figure 1. Steady states of the HPA axis system. Steady-state concentration of CRH (x1), ACTH (x2), GR (x3) and cortisol (x4) as a function of the
external stressor f for the model expressed as system H. The system naturally accommodates 3 stable steady states at rest f=0 and over a broad
range of increasing values for f.
doi:10.1371/journal.pcbi.1000273.g001
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As one might expect the assumptions of ideal control do not
correspond to a physically realizable system. However, the analysis
of the system under idealized conditions allows the study of
possible treatments. Any practical treatment would then be a
suboptimal solution as compared to the treatment under idealized
conditions. This allows proposed treatments to be benchmarked
and compared. In addition, the solution obtained under idealized
conditions can serve as a qualitative guideline for the creation of a
practical, although suboptimal, treatment. In engineering terms
the objective of treatment is to succeed in bring the subject to the
healthy steady-state target while exerting the smallest disturbance
possible to the HPA axis. For example, even though we intend to
manipulate circulating cortisol concentration it should not be
allowed to decrease excessively because of the important role
cortisol plays in regulating a number of cellular and physiological
functions. To avoid such excess perturbations the concentration of
ACTH has been included in the objective function of
Equation 3.This concentration is more readily measured than
that of either CRH or GR making ACTH a good candidate for
monitoring the progress of a treatment.
The optimal control solution that minimizes disruption of
HPA axis function (Eq. 3) is shown in Figure 3 along with the
system’s overall trajectory. Note that the optimal input does
indeed bring the system to the healthy steady-state point. This is
done while maintaining a circulating cortisol concentration that
is near the steady-state value with the exception of a rapid drop
at the start of treatment. The optimal control solution as
computed under the MPC framework has several key features.
The cortisol concentration is rapidly dropped at the outset. Once
this drop in cortisol concentration is achieved, the system
requires little additional control action to come to steady state.
This qualitative information can be used to formulate a
suboptimal control strategy that will bring the system to the
healthy steady state.
A More Clinically Realistic Manipulation of the HPA Axis
System
In this section a suboptimal control strategy is proposed for the
HPA axis system. The goal of this strategy is to mimic the
qualitative results of the MPC solution while being realizable in a
clinical setting. The MPC solution suggests that manipulating
cortisol concentration is a plausible strategy for redirecting the
HPA axis to a healthy steady state. The key difficulty in applying
this approach is determining when the cortisol concentration has
been sufficiently lowered with regard to the other state variables to
allow the system to return to a healthy equilibrium. That is, one
must identify an observable event (corresponding to a measurable
variable) which signals that the steady state of the system has
shifted. In a clinical setting only ACTH and cortisol concentra-
tions, corresponding to x2 and x4, respectively, can be readily
measured. The availability of cortisol analogues makes it possible
to manipulate x4 directly. Therefore as postulated previously
(Eq. 3–4) ACTH (x2) can be used to determine when a change in
available steady state or attractor has occurred. Under the MPC
framework, most of the control action is expended near the initial
time. In Figure 3 the external control action prescribed by MPC
under ideal conditions and the response of ACTH (x2) are both
Figure 2. Migration of cortisol concentration from one stable point to another. Concentration of circulating cortisol plotted as a function of
the external stressor f. A first idealized trajectory (red - -) describes the displacement of the system from rest to a peak cortisol concentration followd
by an eventual lapse into a chronic hypocortisolic state. A second idealized trajectory (green - -) illustrates the effects of treatment. Here removalo f
cortisol can be thought of as a negative stress f. An increase in ACTH concentration of ,30% above baseline serves as a signal that the treatment may
be discontinued.
doi:10.1371/journal.pcbi.1000273.g002
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30% as the system moves from the cusp of multiple candidate
steady states to the basin of a single steady state. The following
treatment is therefore proposed:
Treatment 1 The cortisol concentration in the system should
be slowly decreased until ACTH levels (x2) have increased by more
than 30% relative to the initial condition. Once this signal is
observed, the system’s own natural feedback control action should
restore cortisol levels to normal.
Simulation results for Treatment 1 are shown in Figure 4. As
indicated the system is brought to the healthy steady state via the
suboptimal but more realistic treatment course. Furthermore, the
drop in cortisol concentration is neither as severe nor as sharp as
under naı ¨ve idealized MPC control. A positive outcome may also
be obtained by applying even less severe levels of cortisol
suppression and extending the duration of the treatment. Data
presented in Figure 5 show that a combinations of treatment
duration and cortisol suppression may be varied successfully over a
large range. Nonetheless there exists a minimum level of cortisol
suppression below which the treatment fails regardless of how long
conditions are maintained. Conversely there also exists a minimal
treatment duration below which even severe levels of cortisol
suppression will prove unsuccessful in restoring normal hormone
levels.
Robustness Analyses
The results for Treatment 1 shown in Figure 4 are computed
under nominal conditions. For the proposed treatment to be
clinically useful, it must be effective over a wide variety of
conditions, and parameter values. The robustness of the proposed
approach to changes in the parameter values, initial conditions,
and ambient stress level (i.e., value of d0) is examined in this
section. A direct computational evaluation of robustness of
Treatment 1 is difficult to implement. There are four initial
conditions (x1(0); x2(0); x3(0); x4(0)), seven parameters, and one
disturbance variable (d0). A simulation study where each variable
(initial condition, parameter and disturbance) is evaluated at a
nominal, high and low values, would require, at a minimum
3
12=531,441 simulations. Even if these simulations were com-
pleted, the choice of high, low and nominal value for each variable
would be difficult to justify using available data. An alternative
approach analyzing robustness analysis is to study the asymptotic
behavior of System Hu. Let the concentration of cortisol (x4)b e
manipulated so that the product of cortisiol and GR concentra-
tions (x3x4) is constant. Under these conditions, the asymptotic
value of glucocorticoid receptor concentration GR (x3) is obtained
from Eq. 7 as:
x?
3 ~limt??x3 t ðÞ ~
x3x4 ðÞ
2
kz x3x4 ðÞ
2 zkcr
krd
ð13Þ
The asymptotic value or GR concentration x3‘ has a minimum
as a function of cortisol concentration (x4)a tx 4=0. That is, if one
were to lower the cortisol concentration to zero one would obtain
the lowest possible steady-state value for GR and this value would
be:
GRmin~
kcr
krd
ð14Þ
At the steady-state point given by x4‘=0 and x3‘=k cr/krd the
unique asymptotic solution for CRH (x1) and ACTH (x2) is given
by
Figure 3. Idealized corrective control action. Concentrations of CRH (x1), ACTH (x2), GR (x3) and cortisol (x4) as a function of time in response to
an ideal externally applied perturbation in cortisol u(t). The negative supplement in cortisol signifies a pharmaceutical removal or inactivation of
circulating cortisol. ACTH concentration serves to monitor the progress of the treatment which is discontinued when ACTH increases by ,30% over
baseline.
doi:10.1371/journal.pcbi.1000273.g003
HPA Axis Corrective Control
PLoS Computational Biology | www.ploscompbiol.org 6 January 2009 | Volume 5 | Issue 1 | e1000273Figure 4. A suboptimal but clinically realistic control treatment. Concentrations of CRH (x1), ACTH (x2), GR (x3) and cortisol (x4) as a function
of time in response to a suboptimal but more realistic externally applied perturbation in cortisol u(t). Once again the negative supplement in cortisol
signifies a pharmaceutical removal or inactivation of circulating cortisol. Note a less severe reduction in cortisol is applied over a longer period. The
corresponding ACTH response is slower but the threshold concentration for cessation of treatment remains the same.
doi:10.1371/journal.pcbi.1000273.g004
Figure 5. Balancing intensity and duration of treatment. Diagram of the minimal perturbation in normalized circulating cortisol u(t) as a
function of duration of treatment. In one extreme instance the perturbation in cortisol would be so small that no treatment would be effective
regardless of how much treatment prolonged. Conversely an excessively short treatment would also be ineffective regardless of the intensity of
cortisol reduction.
doi:10.1371/journal.pcbi.1000273.g005
HPA Axis Corrective Control
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It should be noted that the values for GR, CRH and ACTH
identified in Equations 14–15 represent an asymptotic minimum
for the externally controlled system (System Hu). For the closed
loop HPA axis system it represents the minimum achievable
cortisol concentration. Note that this equilibrium point is only
achievable under external input. This result is independent of the
trajectory of the input u(t) and is a property of the HPA axis.
Moreover the solution in Equation 15 is unique indicating that
only a single steady state exists at the minimum for x4R0 and that
this state corresponds to a stable set of non-zero real-valued
concentrations of CRH, ACTH and GR. This result confirms that
reducing the cortisol concentration to a small enough positive
value can indeed take the system to a single stable condition. This
is regardless of the value of d0, parameters, or initial conditions.
This condition will correspond to a healthy equilibrium value
when treatment is administered in the absence of elevated levels of
external stress d0. At high levels of the stressor d0 the success of the
treatment would be short lived as we would simply be immediately
re-administering the same insult originally responsible for the
illness state. This is true regardless of whether the idealized or the
suboptimal treatment approach is used.
Discussion
Patients with CFS have been found to exhibit decreased adrenal
response to ACTH stimulation and lower daily cortisol levels in
plasma, urine and saliva [11,19]. This is a chronic state in these
patients and a detailed model by Gupta et al. [10] suggests that
this condition may correspond to a stable steady state resulting
from the higher order dynamics of the HPA axis. A robust
treatment strategy was estimated using model-based predictive
control methodology involving a controlled reduction of circulat-
ing cortisol concentration. This externally induced reduction in
cortisol concentration is to be maintained until ACTH concen-
trations increase above a critical threshold. Though this treatment
was derived through the use of a numerical model, it nonetheless
provides an interesting conceptual strategy for treatment.
Cortisol output of the HPA axis can in reality be manipulated
either directly or indirectly through several interventions. The
most direct approaches involve (1) inhibition of cortisol synthesis at
the level of the adrenal gland or (2) inhibition of CRH induced
ACTH synthesis by the pituitary. Inhibitors of cortisol synthesis
include pharmaceutical agents such as ketoconazole that have
been used in limited human trials [20]. These are generally used in
the treatment of hypercortisolism in patients and have been known
to cause side effects including decreased androgen and aldosterone
synthesis, elevated pregnenolone, nausea, fever, vomiting and
occasionally hypoadrenalism and liver toxicity [21]. Likewise
CRH antagonists have demonstrated antidepressant and anxio-
lytic properties in animal models of depression [22]. However only
one phase II study involving the treatment of depressed patients
with the CRH antagonist R121919 [23] has been completed thus
far. The inhibition of CRH would not be useful in the current
context as the proposed treatment aims to artificially stimulate an
increase in ACTH concentration.
Indirect approaches to cortisol suppression focus on modulation
of the biochemical feedback returning to the higher HPA axis from
the immune system and the adrenal gland. Inflammatory events
exert a positive immune system feedback to the HPA axis that is
conducted via a number of pro-inflammatory cytokines for which
several components of the HPA axis have receptors. Supported by
immune, epidemiological and small-scale gene expression data
[24], antagonists of the pro-inflammatory cytokine TNF-a have
been used effectively in pilot clinical trials [25] to inhibit this
positive feedback mechanism. The release of pro-inflammatory
cytokines by the immune system can also be manipulated by
altering the immune system’s perception of circulating cortisol.
Dexamethasone is a cortisol analogue that binds to GRII
glucocorticoid receptor with a significantly higher affinity than
that of endogenous cortisol [26,27]. This saturation of the long-
term receptor GRII with dexamethasone promotes down
regulation of cortisol output by dampening the pro-inflammatory
feedback signal. One possible explanation of hypocortisolism is an
enhanced sensitivity to the negative feedback action of cortisol on
the glucocorticoid receptors in what is termed dexamethasone
hyper-suppression [12,28]. Consistent with this mechanism,
patients with CFS have shown a pronounced and prolonged
suppression of salivary cortisol even after relatively low doses of
dexamethasone [29]. Dexamethasone suppression has become a
standard test procedure even though it has a significantly higher
affinity for the GRII receptor over the GRI receptor, does not
bind to corticosteroid binding globulin (CBG) and has a much
longer half-life than endogenous cortisol. Recently Jerjes et al. [30]
developed a similar protocol using prednisolone, a compound with
physiological effects more similar to those of cortisol. Using 5 mg
prednisolone, they achieved a 50% reduction in salivary cortisol in
healthy subjects [30]. Similarly a 52% reduction in salivary cortisol
and an 82% reduction in urinary cortisol were observed in CFS
patients [31]. These relative levels of cortisol suppression are
consistent with those required by this simulated treatment course
and confirm that the system is indeed capable of accommodating
such changes without ill effect.
Unfortunately as in strategies involving the direct inhibition of
CRH, a reduction of positive feedback to the hypothalamus also
leads to a reduction in ACTH synthesis by the pituitary. Recall
that the proposed treatment requires the inhibition of the negative
cortisol feedback without the removal of positive stimulation of
ACTH production. This could be achieved by temporarily
reducing the bioavailability of cortisol itself. Binding proteins
and metabolizing enzymes have been identified for cortisol.
Corticosteroid-binding globulin (CBG) regulates the concentration
of free or active cortisol [32]. Oral oestrogen preparations have
been shown to increase CBG levels [33]. In addition to CBG, the
enzyme 11-b-hydroxysteroid dehydrogenase rapidly inactivates
endogenous glucocorticoid hormones upon entry into the cell [34].
Similarly the multi-drug resistance (MDR) P-glycoprotein (Pgp)
has been shown to control access of cortisol and corticosterone to
the brain [35]. In all cases a reduction in the bioavailability of
cortisol would limit the effect of negative feedback on ACTH
synthesis without hampering the positive feedback from pro-
inflammatory cytokines. ACTH would conceivably accumulate as
a natural consequence of such an imbalance. ACTH could also be
administered directly [36] under these conditions of reduced
cortisol inhibitory feedback to accelerate the treatment course.
Finally the treatment might also be administered at a time of day
that corresponds to the natural circadian reduction in cortisol
secretion.
It should be noted that although the model of HPA axis
dynamics used in this work is currently the most credible model, it
remains in many ways incomplete. For example, there is mounting
data including observations of moderate hypocortisolism in
depressed patients undergoing IFN-a therapy suggesting that
GR receptor function not only affects the release of cytokines but is
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and their signaling pathways on hormone signaling in general, and
GR signaling in particular, is an important area of investigation
regarding both the pathophysiology and treatment of inflamma-
tory and neuropsychiatric diseases. To support these important
aspects of HPA-immune signaling additional detail must be
incorporated into the basic HPA axis model in particular at the
level of the glucocorticoid receptors. Animal studies have not been
exploited in this work but could undoubtedly serve as a basis for
the construction of much more detailed models incorporating
elements that are not readily measured in human experiments
[38]. This is especially true of measurements at the hypothalamus.
By the same token animal studies could be conducted to assess the
tolerance of the overall system to more aggressive treatment and to
determine a practical value for the parameter l as well as the time
period for monitoring and intervention. Certainly chronic and
acute stressors such as the tail suspension test, the forced swim test
and others have been used to produce depression-like symptoms in
mice and have served to study hyperactivity of hypothalamic CRH
neurons [39]. This model has also been used to test the effects of
various anti-depressant therapies [40]. It should be noted however
that CFS is characterized by a hypoactive rather than a
hyperactive HPA axis [41]. Hyperactivity of hypothalamic CRH
neurons observed in major depression produces a blunted ACTH
response to further CRH challenge, likely reflecting a resultant
down-regulation of pituitary CRH receptors [26,37]. In contrast,
subjects with CFS produce less cortisol in response to ACTH
challenge but exhibit exaggerated ACTH responses to CRH [42].
This suggests that CFS hypocortisolism may arise from adrenal
gland adaptation to a sensitized response at the level of the
pituitary and/or the hypothalamus. While convincing murine
models exist for the former condition [39,40], we are not aware of
an equivalent model that mimics the HPA axis hypoactivity
observed in CFS. Models exist nonetheless that reproduce some
facets of chronic fatigue. The most promising of these involve post-
infectious fatigue induced in mice [43,44]. No doubt as our
understanding of the precise molecular signature of CFS improves
so will the fidelity of our animal models enabling us to study CFS
pathophysiology and treatment in earnest.
It is important to note however that while the specific treatment
solution identified using MPC is model-dependent the general
MPC framework is not. Therefore as more detailed models
become available these can easily be exploited to improve a
treatment course. Putting aside issues of model fidelity and
completeness, the proposed MPC framework could still be
exploited in a two-step treatment approach. In a first step data
obtained from a standard dexamethasone test could serve to
calibrate a simple lumped-parameter model capturing the overall
HPA dynamics for a given subject. The calibrated model could
then be used within the proposed MPC framework to estimate the
most appropriate combination of dosage and duration of
treatment for that same patient. Ultimately even if a given model
is not entirely correct our robustness analysis shows that the
desired outcome may be obtained reliably over a wide range of
parameter values. This will be true as long as the structure of the
model is valid.
Conclusion
In conclusion we have demonstrated in this work the use of
model-based predictive control methodology in the estimation of
robust treatment courses for displacing the HPA axis from an
abnormal hypocortisol steady state back to a normal function.
Using this approach on a numerical model of the HPA axis
proposed by Gupta et al. [10] a candidate treatment that displays
robust properties in the face of significant biological variability and
measurement uncertainty requires that cortisol be suppressed for a
short period until ACTH levels exceed 30% of baseline. At this
point the treatment may be discontinued and the HPA axis will
progress to a stable attractor defined by normal hormone profiles.
The concentration of biologically available cortisol could in
principle be altered by binding proteins or metabolizing enzymes
to inhibit negative feedback to the HPA axis without affecting the
synthesis and accumulation of ACTH. Our analysis shows that this
treatment strategy is robust and that a positive outcome can be
obtained reliably for a wide range of treatment efficiencies.
Acknowledgments
Special thanks to the Dr. William C. Reeves and the staff of the Chronic
Viral Diseases Branch at the Centers for Disease Control and Prevention
for many helpful discussions.
Author Contributions
Conceived and designed the experiments: ABZ SDV GB. Performed the
experiments: ABZ GB. Analyzed the data: ABZ GB. Contributed
reagents/materials/analysis tools: ABZ GB. Wrote the paper: ABZ SDV
GB.
References
1. Jacobson L (2005) Hypothalamic-pituitary-adrenocortical axis regulation.
Endocrinol Metab Clin North Am 34(2): 271–292.
2. Silverman MN, Pearce BD, Biron CA, Miller AH (2005) Immune modulation of
the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral
Immunol 18: 41–78.
3. McEwen BS (1996) Gonadal and adrenal steroids regulate neurochemical and
structural plasticity of the hippocampus via cellular mechanisms involving
NMDA receptors. Cell Mol Neurobiol 16: 103–116.
4. Golier JA, Schmeidler J, Legge J, Yehuda R (2007) Twenty-four hour plasma
cortisol and adrenocorticotropic hormone in Gulf War Veterans: relationships to
posttraumatic stress disorder and health symptoms. Biol Psychiatry 62:
1175–1178.
5. Appel S, Chapman J, Shoenfeld Y (2007) Infection and vaccination in chronic
fatigue syndrome: myth or reality? Autoimmunity 40: 48–53.
6. Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, et al. (2004)
Basal circadian and pulsatile ACTH and cortisol secretion in patients with
fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 18: 314–325.
7. Van Den Eede F, Moorkens G, Van Houdenhove B, Cosyns P, Claes SJ (2007)
Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome.
Neuropsychobiology 55: 112–120.
8. Sharma C, Gabrilove JL (1975) A study of the adrenocortical disorders related to
the biosynthesis and regulation of steriod hormones and their computer
simulation. Mt Sinai J Med 42: S2–S39.
9. Bing-Zheng L, Gou-Min D (1991) An improved mathematical model of
hormone secretion in the hypothalamo-pituitary-gonadal axis in man. J Theor
Biol 150: 51–58.
10. Gupta S, Aslakson E, Gurbaxani BM, Vernon SD (2007) Inclusion of the
glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals
bistability. Theor Biol Med Model 4: 8.
11. Cleare AJ (2003) The neuroendocrinology of chronic fatigue syndrome. Endocr
Rev 24: 236–252.
12. Heim C, Ehlert U, Hellhammer DH (2000) The potential role of hypocorti-
solism in the pathophysiology of stress-related bodily disorders. Psychoneur-
oendocrinology 25: 1–35.
13. Glaser R, Kiecolt-Glaser JK (1998) Stress-associated immune modulation:
relevance to viral infections and chronic fatigue syndrome. Am J Med 105:
35S–42S.
14. Clauw DJ, Engel CC Jr, Aronowitz R, Jones E, Kipen HM, et al. (2003)
Unexplained symptoms after terrorism and war: an expert consensus statement.
J Occup Environ Med 45: 1040–1048.
15. Clarke DW, Mohtadi C, Tuffs PS (1987) Generalized predictive control—part I.
the basic algorithm. Automatica 23: 137–148.
16. Clarke DW, Mohtadi C, Tuffs PS (1987) Generalized predictive control—part
II. extensions and interpretations. Automatica 23: 149–160.
17. Camacho EF, Bordons C (1998) Model Predictive Control. London: Springer-
Verlag.
HPA Axis Corrective Control
PLoS Computational Biology | www.ploscompbiol.org 9 January 2009 | Volume 5 | Issue 1 | e100027318. Cox DA, Little JB, O’Shea D (1997) Ideals, Varieties, and Algorithms: An
Introduction to Computational Algebraic Geometry and Commutative Algebra.
New York: Springer-Verlag.
19. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, et al. (1991) Evidence
for impaired activation of the hypothalamic-pituitary-adrenal axis in patients
with chronic fatigue syndrome. J Clin Endocrinol Metab 73: 1224–1234.
20. Van Houdenhove B, Neerinckx E, Lysens R, Vertommen H, Van
Houdenhove L, et al. (2001) Victimization in chronic fatigue syndrome and
fibromyalgia in tertiary care: a controlled study on prevalence and character-
istics. Psychosomatics 42: 21–28.
21. van Denderen JC, Boersma JW, Zeinstra P, Hollander AP, van Neerbos BR
(1992) Physiological effects of exhaustive physical exercise in primary
fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity?
Scand J Rheumatol 21: 35–37.
22. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, et al. (2001) Cortisol
response in the combined dexamethasone/CRH test as predictor of relapse in
patients with remitted depression: a prospective study. J Psychiatr Res 35: 83–94.
23. Modell S, Lauer CJ, Schreiber W, Huber J, Krieg JC, et al. (1998) Hormonal
response pattern in the combined DEX-CRH test is stable over time in subjects
at high familial risk for affective disorders. Neuropsychopharmacology 18:
253–262.
24. Powell R, Ren J, Lewith G, Barclay W, Holgate S, et al. (2003) Identification of
novel expressed sequences, upregulated in the leucocytes of chronic fatigue
syndrome patients. Clin Exp Allergy 33: 1450–1456.
25. Lamprecht K (2001) Pilot study of etanercept treatment in patients with chronic
fatigue syndrome. Meeting of the American Association of Chronic Fatigue
Syndrome (AACFS), Seattle. Available: http://cfsnews.org/accfs-ol.htm.
26. Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression:
relevance to pathophysiology and treatment. Biol Psychiatry 49: 391–404.
27. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998) Brain corticosteroid
receptor balance in health and disease. Endocr Rev 19: 269–301.
28. Fries E, Hesse J, Hellhammer J, Hellhammer DH (2005) A new view on
hypocortisolism. Psychoneuroendocrinology 30: 1010–1016.
29. Gaab J, Hustern D, Peisen R, Engert V, Schad T (2002) Low-dose
dexamethasone suppression test in chronic fatigue syndrome and health.
Psychosom Med 64: 311–318.
30. Jerjes WK, Cleare AJ, Wood PJ, Taylor NF (2006) Assessment of subtle changes
in glucocorticoid negative feedback using prednisolone: comparison of salivary
free cortisol and urinary cortisol metabolites as endpoints. Clin Chim Acta 364:
279–286.
31. Jerjes WK, Taylor NF, Wood PJ, Cleare AJ (2007) Enhanced feedback
sensitivity to prednisolone in chronic fatigue syndrome. Psychoneuroendocrinol-
ogy 32: 192–198.
32. Rosner W (1991) Plasma steroid-binding proteins. Endocrinol Metab Clin North
Am 20: 697–720.
33. Qureshi AC, Bahri A, Breen LA, Barnes SC, Powrie JK, et al. (2007) The
influence of the route of oestrogen administration on serum levels of cortisol-
binding globulin and total cortisol. Clin Endocrinol (Oxf) 66: 632–635.
34. Seckl JR, Walker BR (2001) Minireview: 11b-hydroxysteroid dehydrogenase
type 1—a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:
1371–1376.
35. Karssen AM, Meijer OC, van der Sandt IC, Lucassen PJ, de Lange EC, et al.
(2001) Multidrug resistance P-glycoprotein hampers the access of cortisol but not
of corticosterone to mouse and human brain. Endocrinology 142: 2686–2694.
36. Kirnap M, Colak R, Eser C, Ozsoy O, Tutus A, et al. (2001) A comparison
between low-dose (1 microg), standard-dose (250 microg) ACTH stimulation
tests and insulin tolerance test in the evaluation of hypothalamo-pituitary-
adrenal axis in primary fibromyalgia syndrome. Clin Endocrinol (Oxf) 55:
455–459.
37. Pace TW, Hu F, Miller AH (2007) Cytokine-effects on glucocorticoid receptor
function: relevance to glucocorticoid resistance and the pathophysiology and
treatment of major depression. Brain Behav Immun 21: 9–19.
38. Dunn AJ, Swiergiel AH (2008) The role of corticotropin-releasing factor and
noradrenaline in stress-related responses, and the inter-relationships between the
two systems. Eur J Pharmacol 583: 186–193.
39. Swiergiel AH, Leskov IL, Dunn AJ (2008) Effects of chronic and acute stressors
and CRF on depression-like behavior in mice. Behav Brain Res 186: 32–40.
40. Dhir A, Kulkarni SK (2008) Venlafaxine reverses chronic fatigue-induced
behavioral, biochemical and neurochemical alterations in mice. Pharmacol
Biochem Behav 89: 563–571.
41. Tsigos C, Chrousos GP (2002) Hypothalamic-pituitary-adrenal axis, neuroen-
docrine factors and stress. J Psychosom Res 53: 865–871.
42. Raison CL, Miller AH (2003) When not enough is too much: the role of
insufficient glucocorticoid signaling in the pathophysiology of stress-related
disorders. Am J Psychiatry 160: 1554–1565.
43. Shi L, Smith SE, Malkova N, Tse D, Su Y, et al. (2009) Activation of the
maternal immune system alters cerebellar development in the offspring. Brain
Behav Immun 23: 116–123.
44. Chen R, Moriya J, Yamakawa J, Takahashi T, Li Q, et al. (2008) Brain atrophy
in a murine model of chronic fatigue syndrome and beneficial effect of Hochu-
ekki-to (TJ-41). Neurochem Res 33: 1759–1767.
HPA Axis Corrective Control
PLoS Computational Biology | www.ploscompbiol.org 10 January 2009 | Volume 5 | Issue 1 | e1000273